EUDA Health Holdings Limited announced Shenzhen Inno's approval under the 2025 Shenzhen Key Industry R&D Program for TCR-T cell therapy development, with potential funding up to US$434,688, enhancing EUDA's distribution rights for immunotherapies in Malaysia.
Key takeaways
Shenzhen Inno received approval for its TCR-T therapy project under Shenzhen Key Industry R&D Program, effective January 1, 2026 to December 31, 2028.
Bureau may provide up to US$434,688 in funding for solid tumor TCR-T development.
EUDA holds non-exclusive rights to market Shenzhen Inno's immunotherapies to Malaysia customers via CK Health Plus Sdn Bhd, with treatments in China.
Project uses AI-driven screening, targets HLA-restricted epitopes for Chinese population, and collaborates with Shenzhen Bay Laboratory and others.
Approval aligns with EUDA's strategy to expand access to advanced cellular therapies through commercial channels.